AR119549A1 - RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE - Google Patents

RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE

Info

Publication number
AR119549A1
AR119549A1 ARP200102162A ARP200102162A AR119549A1 AR 119549 A1 AR119549 A1 AR 119549A1 AR P200102162 A ARP200102162 A AR P200102162A AR P200102162 A ARP200102162 A AR P200102162A AR 119549 A1 AR119549 A1 AR 119549A1
Authority
AR
Argentina
Prior art keywords
antigen
binding proteins
binding
binds
bispecific
Prior art date
Application number
ARP200102162A
Other languages
Spanish (es)
Inventor
Gabriele Pszolla
Hofmann Martin Dr
Felix Unverdorben
Meike Hutt
Dominik Maurer
Sebastian Bunk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of AR119549A1 publication Critical patent/AR119549A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente concierne a proteínas de unión a antígeno biespecíficas que están dirigidas contra antígenos diana (AD) que son presentados por el MHC. La misma proporciona en particular proteínas de unión a antígeno biespecíficas que comprenden al menos dos sitios de unión a antígeno (A y B), en las cuales el sitio de unión a antígeno A se une al CD3 y el sitio de unión a antígeno B se une a un complejo formado por el péptido antigénico diana y el MHC. Las proteínas de unión a antígeno biespecíficas de la presente comprenden, en particular, las CDR de los dominios VH y VL de anticuerpos genomodificados anti-CD3 dotados de una afinidad reducida. Las proteínas de unión a antígeno biespecíficas de la presente están destinadas al uso en el diagnóstico, el tratamiento y la prevención de enfermedades asociadas a AD, como las enfermedades cancerosas que expresan antígenos asociados a tumores (AAT). Además, se proporcionan ácidos nucleicos que codifican las proteínas de unión a antígeno biespecíficas de la misma, los vectores que comprenden esos ácidos nucleicos, las células recombinantes que expresan la proteína de unión de antígeno y las composiciones farmacéuticas que comprenden las proteínas de unión a antígeno biespecíficas de la presente.This concerns bispecific antigen-binding proteins that are directed against target antigens (AD) that are presented by the MHC. It provides in particular bispecific antigen-binding proteins comprising at least two antigen-binding sites (A and B), in which the antigen-binding site A binds to CD3 and the antigen-binding site B binds to CD3. binds to a complex formed by the target antigenic peptide and the MHC. The present bispecific antigen-binding proteins comprise, in particular, the CDRs of the VH and VL domains of gene-modified anti-CD3 antibodies endowed with reduced affinity. The present bispecific antigen-binding proteins are intended for use in the diagnosis, treatment, and prevention of AD-associated diseases, such as cancerous diseases that express tumor-associated antigens (TAAs). In addition, nucleic acids encoding the bispecific antigen-binding proteins thereof, vectors comprising those nucleic acids, recombinant cells expressing the antigen-binding protein, and pharmaceutical compositions comprising the antigen-binding proteins are provided. bispecific of the present.

ARP200102162A 2019-08-02 2020-07-31 RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE AR119549A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102019121022.4A DE102019121022A1 (en) 2019-08-02 2019-08-02 Recruiting agent that also binds an MHC molecule

Publications (1)

Publication Number Publication Date
AR119549A1 true AR119549A1 (en) 2021-12-29

Family

ID=74495302

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102162A AR119549A1 (en) 2019-08-02 2020-07-31 RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE

Country Status (2)

Country Link
AR (1) AR119549A1 (en)
DE (1) DE102019121022A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115838432B (en) * 2022-07-08 2023-12-08 浙江大学 Fusion protein for targeted regulation of antigen-specific T cells and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017115966A1 (en) * 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptide molecule with improved dual specificity

Also Published As

Publication number Publication date
DE102019121022A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
JP7097923B2 (en) Antigen binding construct for target molecule
EP3638700B1 (en) Proteinaceous heterodimer and use thereof
PE20211284A1 (en) ANTI-NKG2A ANTIBODIES AND USES OF THEM
RU2018139811A (en) MULTI-SPECIFIC ANTI-BINDING CONSTRUCTIONS TARGETING IMMUNOTHERAPEUTIC MEANS
WO2016150899A3 (en) Anti-ceacam6 antibodies and uses thereof
JP2016531100A5 (en)
EA202091590A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS
CO2022002044A2 (en) Antigen-binding proteins that specifically bind mage-a
JP7341185B2 (en) Antibodies against prostate-specific stem cell antigen and their uses
BR112022001902A2 (en) Bispecific antigen-binding protein, isolated nucleic acid, recombinant host cell, pharmaceutical composition and method for producing the bispecific antigen-binding protein
RU2017114968A (en) BINDING MOLECULES, AND EXACTLY ANTIBODIES, ABLE TO CONTACT L1CAM (CD171)
US11945863B2 (en) CD33-, CD16- and CD123-specific single chain triplebody
PE20241177A1 (en) MESOTHELIN BINDING PROTEINS AND USES THEREOF
AR119549A1 (en) RECRUITMENT AGENT THAT ADDITIONALLY BINDS TO AN MHC MOLECULE
PE20240224A1 (en) BISPECIFIC ANTI-TSPAN8/ANTI-CD3 ANTIBODY AND ANTI-TSPAN8 ANTIBODY
CA3220458A1 (en) Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
AR127360A1 (en) MESOTHELIN BINDING PROTEINS AND USES THEREOF
AU2022241385A9 (en) Anti-vaccinia virus antigen antibodies and related compositions and methods
AR125141A1 (en) ANTI-ALPP / ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
NZ739252A (en) Monoclonal antibodies against bcma
CA3070643A1 (en) Mono and bispecific antibody binding to herg1 and herg1/integrin beta 1
EA201990488A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
NZ739252B2 (en) Monoclonal antibodies against bcma